• 1
    Feldmann M, Maini RN. Anti-TNF α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 16396.
  • 2
    Decker T, Lohmann-Matthes ML, Gifford GE. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 1987; 138: 95762.
  • 3
    Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 4553.
  • 4
    Parry SL, Sebbag M, Feldmann M, Brennan FM. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-α. J Immunol 1997; 158: 367381.
  • 5
    Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 171725.
  • 6
    Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997; 385: 7336.
  • 7
    Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997; 385: 72933.
  • 8
    Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 3929.
  • 9
    Caron G, Delneste Y, Aubry JP, Magistrelli G, Herbault N, Blaecke A, et al. Human NK cells constitutively express membrane TNF-α (mTNFα) and present mTNFα-dependent cytotoxic activity. Eur J Immunol 1999; 29: 358895.
  • 10
    Higuchi M, Nagasawa K, Horiuchi T, Oike M, Ito Y, Yasukawa M, et al. Membrane tumor necrosis factor-α (TNF-α) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation: characterization of membrane TNF-α. Clin Immunol Immunopathol 1997; 82: 13340.
  • 11
    Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 216779.
  • 12
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 13
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594602.
  • 14
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 3545.
  • 15
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 16
    Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 35161.
  • 17
    Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 228.
  • 18
    Mukhtyar C, Luqmani R. Current state of tumour necrosis factor α blockade in Wegener's granulomatosis. Ann Rheum Dis 2005; 64 Suppl 4: iv316.
  • 19
    Schreiber S, Sandborn WJ. CLASSIC-I study the efficacy of adalimumab. Gastroenterology 2006; 130: 192930.
  • 20
    Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 32333; quiz 591.
  • 21
    Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 2519.
  • 22
    Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, et al. Outside-to-inside signal through the membrane TNF-α induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 2001; 166: 1306.
  • 23
    Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α. Gastroenterology 2004; 126: 9345; author reply 935–6.
  • 24
    Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 2005; 128: 37692.
  • 25
    Pocsik E, Duda E, Wallach D. Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells. J Inflamm 1995; 45: 15260.
  • 26
    Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 1939.
  • 27
    Himeji D, Horiuchi T, Tsukamoto H, Hayashi K, Watanabe T, Harada M. Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood 2002; 99: 40708.
  • 28
    Wilkinson RW, Lee-MacAry AE, Davies D, Snary D, Ross EL. Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. J Immunol Methods 2001; 258: 18391.
  • 29
    Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48: 325365.
  • 30
    Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15: 35366.
  • 31
    Dinarello CA. Differences between anti-tumor necrosis factor-α monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 2005; 74: 407.
  • 32
    Shohet JM, Pemberton P, Carroll MC. Identification of a major binding site for complement C3 on the IgG1 heavy chain. J Biol Chem 1993; 268: 586671.
  • 33
    Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 14074.
  • 34
    Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 104552.
  • 35
    Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 2006; 12: 228.
  • 36
    Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005; 174: 48529.
  • 37
    Olleros ML, Guler R, Vesin D, Parapanov R, Marchal G, Martinez-Soria E, et al. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol 2005; 166: 110920.
  • 38
    Corazza N, Brunner T, Buri C, Rihs S, Imboden MA, Seibold I, et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 2004; 127: 81625.
  • 39
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 40
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 21227.